Do analysts rate SPRC or QNRX?

Quoin Pharmaceuticals has a consensus target price of $17.00, indicating a potential upside of 321.84%. Given Quoin Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Quoin Pharmaceuticals is more favorable than SciSparc. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score SciSparc 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Quoin Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50

Which has preferable earnings & valuation, SPRC or QNRX?

SciSparc has higher revenue and earnings than Quoin Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio SciSparc $679K 1.67 -$12.18M N/A N/A Quoin Pharmaceuticals N/A N/A -$15.81M -$25.18 N/A

Is SPRC or QNRX more profitable?

SciSparc's return on equity of 0.00% beat Quoin Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets SciSparc N/A N/A N/A Quoin Pharmaceuticals N/A -489.57% -221.17%

Does the media prefer SPRC or QNRX?

In the previous week, SciSparc had 7 more articles in the media than Quoin Pharmaceuticals. MarketBeat recorded 13 mentions for SciSparc and 6 mentions for Quoin Pharmaceuticals. SciSparc's average media sentiment score of 0.76 beat Quoin Pharmaceuticals' score of 0.74 indicating that SciSparc is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment SciSparc 2 Very Positive mention(s) 0 Positive mention(s) 10 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Quoin Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend SPRC or MBRX?

Moleculin Biotech has a consensus target price of $3.00, suggesting a potential upside of 710.59%. Given Moleculin Biotech's stronger consensus rating and higher probable upside, analysts clearly believe Moleculin Biotech is more favorable than SciSparc. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score SciSparc 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Moleculin Biotech 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33

Which has stronger earnings & valuation, SPRC or MBRX?

SciSparc has higher revenue and earnings than Moleculin Biotech. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio SciSparc $679K 1.67 -$12.18M N/A N/A Moleculin Biotech N/A N/A -$33.56M -$7.13 N/A

Is SPRC or MBRX more profitable?

SciSparc's return on equity of 0.00% beat Moleculin Biotech's return on equity. Company Net Margins Return on Equity Return on Assets SciSparc N/A N/A N/A Moleculin Biotech N/A -143.51% -24.53%

Do analysts recommend ENSC or SPRC?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ensysce Biosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 SciSparc 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable earnings and valuation, ENSC or SPRC?

Ensysce Biosciences has higher earnings, but lower revenue than SciSparc. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Ensysce Biosciences N/A N/A -$10.18M -$2.76 N/A SciSparc $679K 1.67 -$12.18M N/A N/A

Do analysts recommend SPRC or TRAW?

Traws Pharma has a consensus target price of $1.00, suggesting a potential upside of 148.08%. Given Traws Pharma's stronger consensus rating and higher probable upside, analysts plainly believe Traws Pharma is more favorable than SciSparc. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score SciSparc 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Traws Pharma 1 Sell rating(s) 4 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.80

Which has higher earnings & valuation, SPRC or TRAW?

Traws Pharma has higher revenue and earnings than SciSparc. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio SciSparc $679K 1.67 -$12.18M N/A N/A Traws Pharma $2.79M 2.22 $9.17M -$1.74 N/A

Is SPRC or TRAW more profitable?

SciSparc's return on equity of 0.00% beat Traws Pharma's return on equity. Company Net Margins Return on Equity Return on Assets SciSparc N/A N/A N/A Traws Pharma N/A -23,868.92% -165.52%

Do analysts rate OBSV or SPRC?

Given ObsEva's higher probable upside, research analysts clearly believe ObsEva is more favorable than SciSparc. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ObsEva 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SciSparc 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger valuation and earnings, OBSV or SPRC?

SciSparc has higher revenue and earnings than ObsEva. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ObsEva N/A N/A -$58.38M -$0.92 N/A SciSparc $679K 1.67 -$12.18M N/A N/A

Is OBSV or SPRC more profitable?

SciSparc's return on equity of 0.00% beat ObsEva's return on equity. Company Net Margins Return on Equity Return on Assets ObsEva N/A -416.36% -92.01% SciSparc N/A N/A N/A

SciSparc (SPRC) Competitors

$2.00 -1.63 (-44.90%)

Closing price 10/15/2026 04:00 PM Eastern

Extended Trading

$1.84 -0.17 (-8.25%)

As of 07:07 AM Eastern

Compare

SPRC vs. QNRX, MBRX, ENSC, TRAW, and OBSV

Should you buy SciSparc stock or one of its competitors? SciSparc's main competitors and comparable companies include Quoin Pharmaceuticals (QNRX), Moleculin Biotech (MBRX), Ensysce Biosciences (ENSC), Traws Pharma (TRAW), and ObsEva (OBSV). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does SciSparc compare to Quoin Pharmaceuticals?

SciSparc (NASDAQ:SPRC) and Quoin Pharmaceuticals (NASDAQ:QNRX) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, risk, valuation, profitability, earnings and media sentiment.

SciSparc has a beta of 2.83, suggesting that its stock price is 183% more volatile than the broader market. Comparatively, Quoin Pharmaceuticals has a beta of 1.56, suggesting that its stock price is 56% more volatile than the broader market.

25.1% of SciSparc shares are owned by institutional investors. Comparatively, 8.6% of Quoin Pharmaceuticals shares are owned by institutional investors. 1.5% of SciSparc shares are owned by company insiders. Comparatively, 7.5% of Quoin Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Quoin Pharmaceuticals has a consensus target price of $17.00, indicating a potential upside of 321.84%. Given Quoin Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Quoin Pharmaceuticals is more favorable than SciSparc.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SciSparc	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Quoin Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, SciSparc had 7 more articles in the media than Quoin Pharmaceuticals. MarketBeat recorded 13 mentions for SciSparc and 6 mentions for Quoin Pharmaceuticals. SciSparc's average media sentiment score of 0.76 beat Quoin Pharmaceuticals' score of 0.74 indicating that SciSparc is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
SciSparc	2 Very Positive mention(s)	0 Positive mention(s)	10 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Quoin Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

SciSparc has higher revenue and earnings than Quoin Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SciSparc	$679K	1.67	-$12.18M	N/A	N/A
Quoin Pharmaceuticals	N/A	N/A	-$15.81M	-$25.18	N/A

SciSparc's return on equity of 0.00% beat Quoin Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SciSparc	N/A	N/A	N/A
Quoin Pharmaceuticals	N/A	-489.57%	-221.17%

Summary

SciSparc beats Quoin Pharmaceuticals on 8 of the 12 factors compared between the two stocks.

How does SciSparc compare to Moleculin Biotech?

SciSparc (NASDAQ:SPRC) and Moleculin Biotech (NASDAQ:MBRX) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, risk, analyst recommendations, dividends, institutional ownership, valuation, earnings and profitability.

SciSparc has a beta of 2.83, suggesting that its share price is 183% more volatile than the broader market. Comparatively, Moleculin Biotech has a beta of 2, suggesting that its share price is 100% more volatile than the broader market.

In the previous week, SciSparc had 12 more articles in the media than Moleculin Biotech. MarketBeat recorded 13 mentions for SciSparc and 1 mentions for Moleculin Biotech. Moleculin Biotech's average media sentiment score of 1.37 beat SciSparc's score of 0.76 indicating that Moleculin Biotech is being referred to more favorably in the news media.

Company	Overall Sentiment
SciSparc	Positive
Moleculin Biotech	Positive

SciSparc has higher revenue and earnings than Moleculin Biotech.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SciSparc	$679K	1.67	-$12.18M	N/A	N/A
Moleculin Biotech	N/A	N/A	-$33.56M	-$7.13	N/A

SciSparc's return on equity of 0.00% beat Moleculin Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SciSparc	N/A	N/A	N/A
Moleculin Biotech	N/A	-143.51%	-24.53%

Moleculin Biotech has a consensus target price of $3.00, suggesting a potential upside of 710.59%. Given Moleculin Biotech's stronger consensus rating and higher probable upside, analysts clearly believe Moleculin Biotech is more favorable than SciSparc.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SciSparc	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Moleculin Biotech	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

25.1% of SciSparc shares are held by institutional investors. Comparatively, 15.5% of Moleculin Biotech shares are held by institutional investors. 1.5% of SciSparc shares are held by company insiders. Comparatively, 18.0% of Moleculin Biotech shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

SciSparc beats Moleculin Biotech on 7 of the 12 factors compared between the two stocks.

How does SciSparc compare to Ensysce Biosciences?

Ensysce Biosciences (NASDAQ:ENSC) and SciSparc (NASDAQ:SPRC) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, dividends, media sentiment, institutional ownership, valuation, risk, analyst recommendations and earnings.

In the previous week, SciSparc had 12 more articles in the media than Ensysce Biosciences. MarketBeat recorded 13 mentions for SciSparc and 1 mentions for Ensysce Biosciences. Ensysce Biosciences' average media sentiment score of 1.79 beat SciSparc's score of 0.76 indicating that Ensysce Biosciences is being referred to more favorably in the media.

Company	Overall Sentiment
Ensysce Biosciences	Very Positive
SciSparc	Positive

5.6% of Ensysce Biosciences shares are held by institutional investors. Comparatively, 25.1% of SciSparc shares are held by institutional investors. 2.8% of Ensysce Biosciences shares are held by company insiders. Comparatively, 1.5% of SciSparc shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

SciSparc has a net margin of 0.00% compared to Ensysce Biosciences' net margin of -280.53%. SciSparc's return on equity of 0.00% beat Ensysce Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ensysce Biosciences	-280.53%	-2,550.30%	-320.49%
SciSparc	N/A	N/A	N/A

Ensysce Biosciences has a beta of 1, indicating that its stock price has a similar volatility profile to the broader market.Comparatively, SciSparc has a beta of 2.83, indicating that its stock price is 183% more volatile than the broader market.

Ensysce Biosciences has higher earnings, but lower revenue than SciSparc.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ensysce Biosciences	N/A	N/A	-$10.18M	-$2.76	N/A
SciSparc	$679K	1.67	-$12.18M	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ensysce Biosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
SciSparc	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

SciSparc beats Ensysce Biosciences on 7 of the 10 factors compared between the two stocks.

How does SciSparc compare to Traws Pharma?

SciSparc (NASDAQ:SPRC) and Traws Pharma (NASDAQ:TRAW) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, institutional ownership, valuation, profitability, media sentiment, earnings and dividends.

SciSparc's return on equity of 0.00% beat Traws Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SciSparc	N/A	N/A	N/A
Traws Pharma	N/A	-23,868.92%	-165.52%

Traws Pharma has a consensus target price of $1.00, suggesting a potential upside of 148.08%. Given Traws Pharma's stronger consensus rating and higher probable upside, analysts plainly believe Traws Pharma is more favorable than SciSparc.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SciSparc	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Traws Pharma	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80

25.1% of SciSparc shares are owned by institutional investors. Comparatively, 8.0% of Traws Pharma shares are owned by institutional investors. 1.5% of SciSparc shares are owned by company insiders. Comparatively, 7.6% of Traws Pharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

SciSparc has a beta of 2.83, suggesting that its share price is 183% more volatile than the broader market. Comparatively, Traws Pharma has a beta of 1.52, suggesting that its share price is 52% more volatile than the broader market.

In the previous week, SciSparc had 12 more articles in the media than Traws Pharma. MarketBeat recorded 13 mentions for SciSparc and 1 mentions for Traws Pharma. Traws Pharma's average media sentiment score of 1.82 beat SciSparc's score of 0.76 indicating that Traws Pharma is being referred to more favorably in the news media.

Company	Overall Sentiment
SciSparc	Positive
Traws Pharma	Very Positive

Traws Pharma has higher revenue and earnings than SciSparc.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SciSparc	$679K	1.67	-$12.18M	N/A	N/A
Traws Pharma	$2.79M	2.22	$9.17M	-$1.74	N/A

Summary

Traws Pharma beats SciSparc on 7 of the 12 factors compared between the two stocks.

How does SciSparc compare to ObsEva?

ObsEva (NASDAQ:OBSV) and SciSparc (NASDAQ:SPRC) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, risk, analyst recommendations, media sentiment, earnings, valuation, profitability and institutional ownership.

In the previous week, SciSparc had 13 more articles in the media than ObsEva. MarketBeat recorded 13 mentions for SciSparc and 0 mentions for ObsEva. SciSparc's average media sentiment score of 0.76 beat ObsEva's score of 0.00 indicating that SciSparc is being referred to more favorably in the news media.

Company	Overall Sentiment
ObsEva	Neutral
SciSparc	Positive

SciSparc's return on equity of 0.00% beat ObsEva's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ObsEva	N/A	-416.36%	-92.01%
SciSparc	N/A	N/A	N/A

Given ObsEva's higher probable upside, research analysts clearly believe ObsEva is more favorable than SciSparc.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ObsEva	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
SciSparc	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

17.5% of ObsEva shares are held by institutional investors. Comparatively, 25.1% of SciSparc shares are held by institutional investors. 14.4% of ObsEva shares are held by insiders. Comparatively, 1.5% of SciSparc shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

SciSparc has higher revenue and earnings than ObsEva.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ObsEva	N/A	N/A	-$58.38M	-$0.92	N/A
SciSparc	$679K	1.67	-$12.18M	N/A	N/A

ObsEva has a beta of 0.68, suggesting that its share price is 32% less volatile than the broader market. Comparatively, SciSparc has a beta of 2.83, suggesting that its share price is 183% more volatile than the broader market.

Summary

SciSparc beats ObsEva on 9 of the 11 factors compared between the two stocks.

Get SciSparc News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SPRC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SPRC vs. The Competition

Export

Metric	SciSparc	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.05M	$12.46B	$7.31B	$12.93B
Dividend Yield	N/A	2.62%	2.51%	19.61%
P/E Ratio	N/A	653.19	213.39	20.76
Price / Sales	1.67	754.02	580.95	86.44
Price / Cash	N/A	83.43	76.19	51.56
Price / Book	0.15	9.33	10.42	6.01
Net Income	-$12.18M	$2.84B	$3.50B	$380.68M
7 Day Performance	-55.26%	-3.78%	-3.33%	-3.16%
1 Month Performance	-57.26%	-6.96%	-6.59%	-5.20%
1 Year Performance	-94.35%	-4.59%	2.69%	-4.08%

SciSparc Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SPRC SciSparc	0.4474 of 5 stars	$2.00 -44.9%	N/A	-94.8%	$2.05M	$679K	N/A	3	Trending News High Trading Volume
QNRX Quoin Pharmaceuticals	4.1906 of 5 stars	$4.70 -0.4%	$20.00 +325.5%	-73.6%	$9.48M	N/A	N/A	6	Short Interest Decrease Gap Down
MBRX Moleculin Biotech	3.6238 of 5 stars	$0.44 -1.5%	$3.00 +583.5%	-97.1%	$8.68M	N/A	N/A	17	Analyst Forecast Gap Up
ENSC Ensysce Biosciences	1.5007 of 5 stars	$0.43 -0.1%	N/A	-75.8%	$8.36M	$5.07M	N/A	10	Positive News
TRAW Traws Pharma	2.144 of 5 stars	$0.48 -7.9%	$1.00 +108.8%	-85.8%	$7.99M	$2.79M	N/A	7

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SPRC) was last updated on 10/16/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

SciSparc (SPRC) Competitors

SPRC vs. QNRX, MBRX, ENSC, TRAW, and OBSV

How does SciSparc compare to Quoin Pharmaceuticals?

Summary

How does SciSparc compare to Moleculin Biotech?

Summary

How does SciSparc compare to Ensysce Biosciences?

Summary

How does SciSparc compare to Traws Pharma?

Summary

How does SciSparc compare to ObsEva?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SPRC vs. The Competition

SciSparc Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

SciSparc (SPRC) Competitors

SPRC vs. QNRX, MBRX, ENSC, TRAW, and OBSV

How does SciSparc compare to Quoin Pharmaceuticals?

Which has more volatility & risk, SPRC or QNRX?

Do institutionals and insiders have more ownership in SPRC or QNRX?

Do analysts rate SPRC or QNRX?

Does the media prefer SPRC or QNRX?

Which has preferable earnings & valuation, SPRC or QNRX?

Is SPRC or QNRX more profitable?

Summary

How does SciSparc compare to Moleculin Biotech?

Which has more volatility and risk, SPRC or MBRX?

Does the media prefer SPRC or MBRX?

Which has stronger earnings & valuation, SPRC or MBRX?

Is SPRC or MBRX more profitable?

Do analysts recommend SPRC or MBRX?

Do institutionals & insiders hold more shares of SPRC or MBRX?

Summary

How does SciSparc compare to Ensysce Biosciences?

Does the media refer more to ENSC or SPRC?

Do institutionals and insiders believe in ENSC or SPRC?

Is ENSC or SPRC more profitable?

Which has more risk & volatility, ENSC or SPRC?

Which has preferable earnings and valuation, ENSC or SPRC?

Do analysts recommend ENSC or SPRC?

Summary

How does SciSparc compare to Traws Pharma?

Is SPRC or TRAW more profitable?

Do analysts recommend SPRC or TRAW?

Do insiders and institutionals have more ownership in SPRC or TRAW?

Which has more volatility & risk, SPRC or TRAW?

Does the media favor SPRC or TRAW?

Which has higher earnings & valuation, SPRC or TRAW?

Summary

How does SciSparc compare to ObsEva?

Does the media refer more to OBSV or SPRC?

Is OBSV or SPRC more profitable?

Do analysts rate OBSV or SPRC?

Do institutionals & insiders have more ownership in OBSV or SPRC?

Which has stronger valuation and earnings, OBSV or SPRC?

Which has more risk & volatility, OBSV or SPRC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SPRC vs. The Competition

SciSparc Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools